Saltar al contenido
Merck

D0500000

Desipramine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C18H22N2 · HCl
Número de CAS:
Peso molecular:
302.84
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

desipramine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl[H].CNCCCN1c2ccccc2CCc3ccccc13

InChI

1S/C18H22N2.ClH/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20;/h2-5,7-10,19H,6,11-14H2,1H3;1H

InChI key

XAEWZDYWZHIUCT-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Desipramine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Richard M O'Connor et al.
Pharmacology, biochemistry, and behavior, 103(3), 561-567 (2012-10-13)
The neurotransmitter glutamate is increasingly being implicated as playing a role in the molecular pathology underlying depression. The group III family of metabotropic glutamate (mGlu) receptors (mGlu(4,) mGlu(7) and mGlu(8) receptors) remains the most poorly investigated of all glutamate receptors
Maria Stratinaki et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(20), 8254-8259 (2013-05-01)
Regulator of G protein signaling 4 (Rgs4) is a signal transduction protein that controls the function of monoamine, opiate, muscarinic, and other G protein-coupled receptors via interactions with Gα subunits. Rgs4 is expressed in several brain regions involved in mood
Thomas M Polasek et al.
British journal of clinical pharmacology, 75(4), 1019-1028 (2012-08-29)
To determine the effect of increasing adult age on predicted metabolic drug clearance. Predicted metabolic drug clearances (CLPT ) were determined using in vitro-in vivo extrapolation coupled with physiological-based pharmacokinetic modelling and simulation (IVIVE-PBPK) in Simcyp®. Simulations were conducted using
Alain Watts et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 32(39), 13411-13420 (2012-09-28)
Rapid eye movement (REM) sleep enhances hippocampus-dependent associative memory, but REM deprivation has little impact on striatum-dependent procedural learning. Antidepressant medications are known to inhibit REM sleep, but it is not well understood if antidepressant treatments impact learning and memory.
O F O'Leary et al.
Neuroscience, 228, 36-46 (2012-10-17)
Approximately 50% of patients with a major depressive episode fail to achieve remission with first-line antidepressant treatments. Second-line treatment strategies for such patients include lithium augmentation of antidepressants, particularly with tricyclic antidepressants. The neurobiological mechanisms underlying the therapeutic effects of

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico